Abstracts
PO57
Molecular Cytogenetic Characteristics of Multiple Myeloma Patients Treated at KFSHRC Jeddah
Syeda Abbas, MD – Assistant Consultant of adult hematology & TCT, Oncology, KFSHRC Jeddah; Nouran Alhashimi, MD – Specialist of adult hematology & TCT, Oncology, KFSHRC Jeddah; Nawaf Alhazmi, MD – F2 Fellow of adult hematology & TCT, Oncology, KFSHRC Jeddah; Elaf Bahanshal, MD – Assistant Consultant of adult hematology & TCT, Oncology, KFSHRC Jeddah; Noof Barayan, MD – F1 Fellow of adult hematology & TCT, Oncology, KFSHRC Jeddah; Noha Eisa, MD – Assistant Consultant of adult hematology & TCT, Oncology, KFSHRC Jeddah; Rasha Mahmoud, MD – F2 Fellow of adult hematology & TCT, Oncology, KFSHRC Jeddah; Ammar Moahmmad, MD – F2 Fellow of adult hematology & TCT, Oncology, KFSHRC Jeddah; Mohammed Mohammed, MD – Assistant Consultant of adult hematology & TCT, Oncology, KFSHRC Jeddah; Masud Nabi, MD – Assistant Consultant of adult hematology & TCT, Oncology, KFSHRC Jeddah; Rozina Qureshi, MD – Assistant Consultant of adult hematology & TCT, Oncology, KFSHRC Jeddah; Abeer Samman, MD – F1 Fellow of adult hematology & TCT, Oncology, KFSHRC Jeddah; Reem Zabani, MD – F2 Fellow of adult hematology & TCT, Oncology, KFSHRC Jeddah
Introduction/Background/Significance:
Multiple Myeloma (MM) is a Hematological malignancy of B-cell plasma cell that affects elderly population. It is the second most common malignancy after lymphoma. Little is known about the disease characteristics among Saudi population. We are here reporting the retrospective analysis of molecular cytogenetic characteristics of MM among Saudi patientsMaterials and Methods/Case Presentation/Objective:
In the period of January 1st 2019 till March 31st, 2024 all patients with MM were identified through our oncology data unit (ODU) after IRB approval (IRB 2023-94). A case reporting form was used (CRF) for data collection, and there is no conflict of interest.
Results/Description/Main Outcome Measure(s):
Over a period of 5 years a total of 54 patients were identified, among these 33 were men representing 33/54 (61%) and 21 were women representing 21/54 (39%). The median age was 61-70 years 16/54 (30%). The molecular cytogenetic studies were performed. None of the performed chromosomal studies showed any dividing cells at any time. FISH cytogenetic studies were not available in 34/54 (63%) of patients, while results were normal in 12/20 (60%) of patients who had FISH performed. Only 8/20 (40%) showed abnormal cytogenetic results. TP53 mutation was seen in 2/8 (25%), whereas t(11;14), 13q(del), & Hypodiploidy were each seen in 3/8 (38%) respectively
Conclusion(s).:
Despite the diagnostic, prognostic, & therapeutic implication of molecular cytogenetic studies in patients with MM there is a need for an inhouse assessment method of our patients with MMTrademarked Items:
References:
